Evidence shows that the hyperactivation of KRAS prevents both the innate and adaptive immunity by regulating the expression of immune checkpoint CD47 and PD-L1, activating immune suppressive cells, modulating the level of major histocompatibility complex class I (MHC), forming an inconvenient stromal microenvironment and so forth (cancer cell p2). This evidence concerns the gene CD47 and cancer.